Zacks Research Weighs in on Veeva Systems Inc.'s Q1 2025 Earnings (NYSE:VEEV)

Veeva Systems Inc. (NYSE:VEEV - Free Report) - Investment analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Veeva Systems in a research note issued on Tuesday, May 21st. Zacks Research analyst R. Department now anticipates that the technology company will post earnings of $0.90 per share for the quarter, down from their prior forecast of $0.91. The consensus estimate for Veeva Systems' current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Veeva Systems' Q2 2025 earnings at $0.97 EPS, FY2025 earnings at $3.97 EPS, Q1 2026 earnings at $1.02 EPS, Q3 2026 earnings at $1.04 EPS, FY2026 earnings at $4.31 EPS and Q1 2027 earnings at $1.23 EPS.

A number of other research firms have also recently issued reports on VEEV. Jefferies Financial Group boosted their target price on Veeva Systems from $225.00 to $270.00 and gave the company a "buy" rating in a research note on Monday, March 4th. UBS Group boosted their target price on Veeva Systems from $185.00 to $235.00 and gave the company a "neutral" rating in a research note on Monday, February 26th. Citigroup boosted their target price on Veeva Systems from $240.00 to $264.00 and gave the company a "buy" rating in a research note on Friday, March 1st. StockNews.com raised Veeva Systems from a "hold" rating to a "buy" rating in a research note on Friday, April 12th. Finally, JPMorgan Chase & Co. boosted their target price on Veeva Systems from $183.00 to $222.00 and gave the company a "neutral" rating in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Veeva Systems has an average rating of "Moderate Buy" and an average target price of $234.90.

Veeva Systems Stock Down 0.3 %

NYSE VEEV traded down $0.69 on Friday, reaching $203.89. The company had a trading volume of 592,087 shares, compared to its average volume of 907,643. The stock's 50 day moving average is $211.60 and its 200-day moving average is $203.17. The stock has a market cap of $32.89 billion, a price-to-earnings ratio of 63.53, a PEG ratio of 1.97 and a beta of 0.76. Veeva Systems has a 52 week low of $161.39 and a 52 week high of $236.90.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. The business had revenue of $630.62 million during the quarter, compared to the consensus estimate of $620.75 million. Veeva Systems had a return on equity of 11.26% and a net margin of 22.24%.

Hedge Funds Weigh In On Veeva Systems

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Veeva Systems by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 14,150,070 shares of the technology company's stock worth $3,278,430,000 after acquiring an additional 991,208 shares during the period. Wellington Management Group LLP increased its stake in Veeva Systems by 9.6% during the 3rd quarter. Wellington Management Group LLP now owns 3,315,304 shares of the technology company's stock worth $674,499,000 after acquiring an additional 289,133 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Veeva Systems by 6.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,167,960 shares of the technology company's stock worth $417,376,000 after acquiring an additional 122,546 shares during the period. Van ECK Associates Corp increased its stake in Veeva Systems by 9.0% during the 1st quarter. Van ECK Associates Corp now owns 1,934,150 shares of the technology company's stock worth $448,123,000 after acquiring an additional 159,085 shares during the period. Finally, FMR LLC increased its stake in Veeva Systems by 15.4% during the 3rd quarter. FMR LLC now owns 1,833,135 shares of the technology company's stock worth $372,951,000 after acquiring an additional 244,599 shares during the period. Institutional investors own 88.20% of the company's stock.

Insider Activity at Veeva Systems

In other Veeva Systems news, Director Timothy S. Cabral sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $226.04, for a total value of $3,390,600.00. Following the sale, the director now owns 23,391 shares in the company, valued at $5,287,301.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Veeva Systems news, EVP Alan Mateo sold 3,391 shares of the company's stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $200.86, for a total value of $681,116.26. Following the sale, the executive vice president now owns 21,983 shares in the company, valued at $4,415,505.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy S. Cabral sold 15,000 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $226.04, for a total value of $3,390,600.00. Following the transaction, the director now owns 23,391 shares in the company, valued at approximately $5,287,301.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,989 shares of company stock valued at $4,818,013. Insiders own 10.50% of the company's stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.